Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer.

Background: Sentinel lymph node biopsy (SLNB) provides staging information and guides adjuvant therapy in early breast cancer (EBC). Routine SLNB in oncogeriatricians with low-risk EBC remains controversial. Aims: To evaluate axillary management in elderly patients diagnosed with oestrogen receptor...

Descripción completa

Detalles Bibliográficos
Publicado en:Breast Cancer: Basic & Clinical Research pp. 1 - 14
Autores principales: Davey, Matthew G, Ryan, Éanna J, Burke, Daniel, McKevitt, Kevin, McAnena, Peter F, Kerin, Michael J, Lowery, Aoife J
Formato: research tables/charts Journal Article
Publicado: Sage Publications Inc. 6/14/2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150912139&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 150912139
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11782234
        B078
      jtl: Breast Cancer: Basic & Clinical Research
      issn: 11782234
      maglogo: Y
    pubinfo:
      dt: 6/14/2021
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        150912139
        150912139
        150912139
        10.1177/11782234211022203
        150912139
      ppf: 1
      ppct: 13
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer.
      aug:
        au:
          Davey, Matthew G
          Ryan, Éanna J
          Burke, Daniel
          McKevitt, Kevin
          McAnena, Peter F
          Kerin, Michael J
          Lowery, Aoife J
        affil: Department of Surgery, Galway University Hospitals, Galway, Republic of Ireland
      sug:
        subj:
          Hormone Receptor Positive Breast Neoplasms Diagnosis
          Hormone Receptor Positive Breast Neoplasms Therapy
          Sentinel Lymph Node Biopsy Utilization
          Chemotherapy, Adjuvant
          Early Intervention
          Axilla Physiopathology
          Decision Making, Clinical
          Human
          Female
          Aged
          Axillary Lymph Node Dissection
          Aged, 80 and Over
          Descriptive Statistics
          Kaplan-Meier Estimator
          Survival
          Cancer Patients
          Oncogenes
          Odds Ratio
          Confidence Intervals
          Individualized Medicine
          Data Analysis Software
          Aged: 65+ years
          Aged, 80 & over
          Female
      ab: Background: Sentinel lymph node biopsy (SLNB) provides staging information and guides adjuvant therapy in early breast cancer (EBC). Routine SLNB in oncogeriatricians with low-risk EBC remains controversial. Aims: To evaluate axillary management in elderly patients diagnosed with oestrogen receptor positive (ER+), clinically lymph node negative (cLN−) EBC, and to assess whether SLNB affects further axillary management or adjuvant chemotherapy (ACTX) decision making. Methods: Female patients aged > 65 years, diagnosed with ER+, human epidermal growth factor receptor-2 negative (HER2−), and cLN− breast cancer (BC), who underwent surgery and SLNB were included. Clinicopathological predictors of ACTX and completion axillary lymph node dissection (CALND) were determined. Kaplan-Meier analyses assessed survival outcomes. Results: A total of 253 patients were included (median age: 72 years, range: 66-90), all underwent SLNB; 50 (19.8%) had lymphatic metastasis on SLNB (SLNB+). Of these, 19 proceeded to CALND (38.0%), 10 (52.6%) of whom had further axillary disease (ALND+). 20 of the 50 SLNB+ patients received ACTX (40.0%) as did 31 of the 203 SLNB− patients (15.2%) (P <.001). Oncotype DX (ODX) testing was utilized in 82 cases (32.8%). Younger age (P <.001), SLNB+ (P <.001) and ODX score (P =.003) were all associated with ACTX prescription. ODX > 25 (OR: 4.37, 95% CI: 1.38-13.80, P =.012) independently predicted receiving ACTX. Receiving ACTX and proceeding to CALND did not improve disease-free (P =.485 and P =.345) or overall survival (P =.981 and P =.646). Conclusions: Routine SNLB may not be necessary in elderly patients diagnosed with ER+, cLN− EBC. Future oncogeriatric practice is likely to see genomic testing guiding ACTX prescription in this group.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N